ClinicalTrials.gg
CompletedNCT01222520Updated Jun 27, 2014Results posted

Telmisartan 80mg Non-responder Trial

A Phase 3 interventional study of Telmisartan and amlodipine and Telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed at 4 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
52nd of 99
174 · median 184
Started
2010
with 5 others
Phase 3
40 of 99
none open now
Registered
43rd of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 52nd largest by enrollment, is one of 6 that started in 2010, is one of 40 in phase 3, and was the 43rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly.

In the Japanese 3x3 factorial trial of telmisartan and hydrochlorothiazide in essential hypertension patients whose diastolic blood pressure (DBP) are equal or more than 95 mmHg, the DBP control rate (less than 90 mmHg) after 8 weeks treatment of the telmisartan 80 mg monotherapy group (66 patients) was 41.5%. There should be medical needs of the telmisartan 80 mg and amlodipine 5 mg fixed dose combination because some patients cannot have his or her blood pressure controlled with telmisartan 80 mg.

Thus, this clinical trial is being conducted to evaluate the antihypertensive effect and safety of a fixed-dose combination (FDC) drug of 2 antihypertensive agents with different pharmacological effects, telmisartan 80 mg and amlodipine 5 mg (T80/A5 mg), compared with telmisartan 80 mg (T80 mg) monotherapy in Japanese patients with essential hypertension who fail to respond adequately to treatment with the maximum dose of telmisartan 80 mg monotherapy. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Essential hypertensive patients

    • If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg
    • If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg
  • Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.

Exclusion criteria

Exclusion criteria:

  • Patients taking 3 or more antihypertensive drugs at signing the form
  • Patients with known or suspected secondary hypertension
  • Patients with cardiac arrhythmia
  • Congestive heart failure with (NYHA) functional class III-IV
  • Patients with recent cardiovascular events
  • Patients with a history of stroke or within last 6 months before signing the informed consent form
  • Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
  • Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
  • Patients with known to any component of the product, or a known hypersensitivity to dihydropyridine-derived drugs
  • Patients with hepatic and/or renal dysfunction
  • Pre-menopausal women who are nursing or pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
174 participants (actual)

Study arms

  • Experimental
    Telmisartan and amlodipine FDC

    once a daily

    Drug: Telmisartan and amlodipine

  • Active comparator
    Telmisartan monotherapy

    once a daily

    Drug: Telmisartan

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough

    Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough

    Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

    Time frame: Baseline, 8 weeks

  2. Seated DBP Control Rate at Trough

    DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  3. Seated SBP Control Rate at Trough

    SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  4. Seated DBP Response Rate at Trough

    DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline ≥10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  5. Seated SBP Response Rate at Trough

    SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline ≥20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

  6. Seated Blood Pressure (BP) Normalisation at Trough

    Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing

    Time frame: 8 weeks

07

Results

Posted Jul 4, 2012

Participant flow

Open-label run-in Period
Participant flow — Open-label run-in Period
MilestoneTelmisartan and Amlodipine FDCTelmisartan
Started0197
Completed0174
Not completed023
Withdrew: Withdrawal by subject02
Withdrew: Blood pressure criteria not met018
Withdrew: Number of patients fulfilled03
Double-blind Period
Participant flow — Double-blind Period
MilestoneTelmisartan and Amlodipine FDCTelmisartan
Started8787
Completed8685
Not completed12
Withdrew: Adverse event01
Withdrew: Lack of efficacy01
Withdrew: Study medication stolen10

Outcome measures

PrimaryReduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough

Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
mmHgTelmisartan and Amlodipine FDCTelmisartan
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough12.28 ± 0.733.14 ± 0.74
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · ANCOVA · p = <0.0001 · Least square mean difference: 9.14 · 95% CI 7.09 to 11.18
SecondaryReduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough

Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

Time frame:
Baseline, 8 weeks
Reported as:
Least squares mean · mmHg
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
mmHgTelmisartan and Amlodipine FDCTelmisartan
Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough18.37 ± 1.103.49 ± 1.10
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · ANCOVA · p = <0.0001 · Least square mean difference: 14.88 · 95% CI 11.82 to 17.94
SecondarySeated DBP Control Rate at Trough

DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Seated DBP Control Rate at Trough
Percentage of participantsTelmisartan and Amlodipine FDCTelmisartan
No29.973.3
Yes70.126.7
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · Fisher Exact · p = <0.0001
SecondarySeated SBP Control Rate at Trough

SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Seated SBP Control Rate at Trough
Percentage of participantsTelmisartan and Amlodipine FDCTelmisartan
No26.071.2
Yes74.028.8
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · Fisher Exact · p = <0.0001
SecondarySeated DBP Response Rate at Trough

DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (\<90 mmHg and/or reduction from reference baseline ≥10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Seated DBP Response Rate at Trough
Percentage of participantsTelmisartan and Amlodipine FDCTelmisartan
No19.569.8
Yes80.530.2
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · Fisher Exact · p = <0.0001
SecondarySeated SBP Response Rate at Trough

SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (\<140 mmHg and/or reduction from reference baseline ≥20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Seated SBP Response Rate at Trough
Percentage of participantsTelmisartan and Amlodipine FDCTelmisartan
No11.548.8
Yes88.551.2
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · Fisher Exact · p = <0.0001
SecondarySeated Blood Pressure (BP) Normalisation at Trough

Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing

Time frame:
8 weeks
Reported as:
Number · Participants
Seated Blood Pressure (BP) Normalisation at Trough
ParticipantsTelmisartan and Amlodipine FDCTelmisartan
No2866
Optimal212
Normal227
High-normal1611
Statistical analysis
  • Telmisartan and Amlodipine FDC vs Telmisartan · Cochran-Mantel-Haenszel · p = <0.0001

Adverse events

Collected over From drug administration in the double blind treatment period until 24 hours after the last dosing, up to 63 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan and Amlodipine FDC—0/87 (0%)5/87 (5.7%)
Telmisartan—0/87 (0%)2/87 (2.3%)
Most frequent other events
Most frequent other events
EventTelmisartan and Amlodipine FDCTelmisartan
NasopharyngitisInfections and infestations5/872/87

Baseline characteristics

Age, Continuous
Age, Continuous(year)Telmisartan and Amlodipine FDCTelmisartanTotal
Mean54.5 ± 9.054.8 ± 8.654.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Telmisartan and Amlodipine FDCTelmisartanTotal
Female201333
Male6774141
08

Study locations

4 sites
  • 1235.36.01 Boehringer Ingelheim Investigational Site
    Chuo-ku,Tokyo, Japan
  • 1235.36.04 Boehringer Ingelheim Investigational Site
    Hiroshima, Hiroshima, Japan
  • 1235.36.02 Boehringer Ingelheim Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • 1235.36.03 Boehringer Ingelheim Investigational Site
    Suita, Osaka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010 and a primary completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Oct 18, 2010
Start
Oct 2010
Primary completionActual
Jun 2011
Results first posted
Jul 4, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01222520
Responsible party
Sponsor
First posted
Oct 18, 2010
Start date
Oct 2010
Primary completion
Jun 2011
Results posted
Jul 4, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion